Dallas Conference • April 8-9, 2016

The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences cover topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.

12:00-12:40 PM Lunch
12:50-1:00 PM Welcome/Introduction Conference Chairs:
Mack Mitchell, MD, and Lawrence R. Schiller, MD
Viral Hepatitis
1:00-1:25 PM HCV: Resistance, DAA failures and other difficult situations Eric Lawitz, MD
1:25-1:50 PM HCV: Renal failure, advanced cirrhotics and liver cancer risk after cure Norah A. Terrault, MD
1:50-2:15 PM Debate: Treatment options for HCV GT1 and GT3 patients…the pros and cons of DAA class combinations Faculty: Paul Kwo, MD, Norah Terrault, MD and Eric Lawitz, MD

Fred Poordad, MD
2:15-2:40 PM HBV: Future development and novel mechanisms of action Paul Kwo, MD
2:40-3:05 PM Q&A/Panel Discussion
3:05-3:20 PM Break
Functional Gastrointestinal Disorders
3:20-3:45 PM Sphincter of Oddi dysfunction Paul R. Tarnasky, MD
3:45-4:10 PM Patient management update: chronic constipation Lawrence R. Schiller, MD
4:10-4:45 PM Manipulating the microbiome to treat IBS Christopher Chang, MD, PhD
4:45-5:15 PM Q&A/Panel Discussion
5:15-5:30 PM Day 1 Wrap Up
5:30-7:00 PM Welcome Reception
7:30-8:15 AM Breakfast
8:25-8:30 AM Welcome Conference Chairs:
Mack Mitchell, MD and Lawrence R. Schiller, MD
Upper Gastrointestinal Disorders
8:30-9:00 AM Eosinophilic esophagitis Joel Richter, MD
9:00-9:30 AM Nonmedical therapeutic modalities for GERD: What's in the toolbox? Ronnie Fass, MD
9:30-10:00 AM Refractory GERD: Residual reflux or something else? Michael F. Vaezi, MD, PhD, MSc
10:00-10:30 AM Q&A/Panel Discussion
10:30-10:45 AM Break
10:45-11:45 AM Parallel Sessions (see below for options)
11:45 AM -12:00 PM Retrieve Lunch
12:00-12:50 PM Lunch
Managing Chronic Liver Disease
1:00-1:25 PM Management of NAFLD/NASH: Diagnostic modalities and future treatment options Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD
1:25-1:50 PM Management of alcoholic liver disease Mack Mitchell, MD
1:50-2:15 PM Management of PBC, PSC, and autoimmune hepatitis Fred Poordad, MD
2:15-2:40 PM Q&A/Panel Discussion
2:40-2:50 PM Break
Inflammatory Bowel Disease (IBD)
2:50-3:15 PM Dilemmas in the management of ulcerative colitis in 2016 Stephen B. Hanauer, MD
3:15-3:40 PM Dilemmas in the management of Crohn's disease in 2016 Dario R. Sorrentino, MD, FRACP
3:40-4:05 PM Implementing the new IBD guidelines to improve patient outcomes Themistocles Dassopoulos, MD
4:05-4:30 PM Q&A/Panel Discussion
4:30-4:45 PM Meeting Wrap Up/Close
1 Inflammatory Bowel Disease
2 Functional GI Disorders
3 Upper GI Disorders
4 Viral Hepatitis and Complications of Cirrhosis: Therapy Decision Making

This activity is supported by educational grants from AbbVie Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.; and Takeda Pharmaceuticals U.S.A., Inc.

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower, the Gastrointestinal and Liver Association of the Americas (GALA), and the Texas Liver Institute.